Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003

Trial Profile

Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 29 Jul 2015 Status changed from active, no longer recruiting to completed ClinicalTrials.gov record.
    • 02 May 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
    • 02 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top